153 related articles for article (PubMed ID: 37830451)
1. Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Koch MW; Moral E; Brieva L; Mostert J; Strijbis EM; Comtois J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Cutter G
Mult Scler; 2023 Dec; 29(14):1776-1785. PubMed ID: 37830451
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
[TBL] [Abstract][Full Text] [Related]
3. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Eur J Neurol; 2022 Apr; 29(4):1106-1116. PubMed ID: 34927308
[TBL] [Abstract][Full Text] [Related]
4. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
6. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.
Scalfari A; Neuhaus A; Degenhardt A; Rice GP; Muraro PA; Daumer M; Ebers GC
Brain; 2010 Jul; 133(Pt 7):1914-29. PubMed ID: 20534650
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
9. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
10. Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
Koch MW; Mostert J; Zhang Y; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Neurology; 2021 Sep; 97(13):e1334-e1342. PubMed ID: 34376508
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908
[TBL] [Abstract][Full Text] [Related]
13. The impact of relapse definition and measures of durability on MS clinical trial outcomes.
Satyanarayan S; Cutter G; Krieger S; Cofield S; Wolinsky JS; Lublin F
Mult Scler; 2023 Apr; 29(4-5):568-575. PubMed ID: 37119208
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
15. Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
Strijbis EM; Coerver E; Mostert J; van Kempen ZLE; Killestein J; Comtois J; Repovic P; Bowen JD; Cutter G; Koch M
J Neurol Neurosurg Psychiatry; 2023 Oct; 94(10):792-799. PubMed ID: 37173129
[TBL] [Abstract][Full Text] [Related]
16. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
[TBL] [Abstract][Full Text] [Related]
18. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Freedman MS; Pozzilli C; Havrdova EK; Lemle A; Burcklen M; Larbalestier A; Hennessy B; Sidorenko T; Vaclavkova A; Olsson T;
Neurology; 2022 Aug; 99(8):e762-e774. PubMed ID: 35667837
[TBL] [Abstract][Full Text] [Related]
19. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
Novotna M; Paz Soldán MM; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Noseworthy JH; Weinshenker BG; Rodriguez M; Kantarci OH
Neurology; 2015 Aug; 85(8):722-9. PubMed ID: 26208962
[TBL] [Abstract][Full Text] [Related]
20. How patients with multiple sclerosis acquire disability.
Lublin FD; Häring DA; Ganjgahi H; Ocampo A; Hatami F; Čuklina J; Aarden P; Dahlke F; Arnold DL; Wiendl H; Chitnis T; Nichols TE; Kieseier BC; Bermel RA
Brain; 2022 Sep; 145(9):3147-3161. PubMed ID: 35104840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
